NVO ▼ -1.9% - Novo Nordisk A/S $NVO Novo Nordisk: STEP Young Phase 3 Meets Primary Endpoint as Two Heart-Disease Studies Are Halted ? • In STEP Young, 40.4% of children aged 6 to under 12 treated with semaglutide plus lifestyle modification were no longer classified as having obesity after 68 weeks, versus 0% on placebo. • The 165-patient trial met its primary endpoint, with safety and tolerability consistent with previous semaglutide trials and no new concerns identified for growth or pubertal development. • Separately, Novo Nordisk has stopped two additional studies involving an experimental heart-disease drug, marking another setback for the program. Novo Nordisk's semaglutide achieved its primary endpoint in the STEP Young trial, with 40.4% of children aged 6 to under 12 no longer classified as obese after 68 weeks compared to 0% on placebo, and no new safety concerns identified. However, the company simultaneously halted two studies of an experimental heart-disease drug, signaling a setback in that program and likely offsetting investor optimism from the pediatric obesity success. 07-SEP-2026 08:19 AM ET